RxDoctor Payments DataLook up a doctor →

William Wilson, MD

Rheumatology · Atlanta, GANPI 1063587061

Payments from drug & device makers

$344,426in general payments, 2019–2025

Across 2,167 payments — averaging $158.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$94K
  • Amgen$80K
  • Johnson & Johnson$48K
  • GSK$39K
  • Mallinckrodt Hospital Products Inc.$28K
  • Mallinckrodt Enterprises LLC$16K
  • plus $40K from 48 others

What the payments were for

  • Consulting fees$14,5134%
  • Speaking & faculty fees$254,20674%
  • Travel & lodging$27,4038%
  • Food & beverage$47,52414%
  • Education$7400%
  • Gifts$410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$344,426 in reported general payments places this provider in the 90th percentile of 177 rheumatology providers in Georgia.

See all rheumatology providers in Georgia

Medicare billing

Part B allowed, 2024
$2,302,519
Medicare patients
431
Services billed
144,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ActharCorticotropin11$1,031,861
RinvoqUpadacitinib117$782,281
Enbrel SureclickEtanercept59$623,088
KrystexxaPegloticase18$513,071
Xeljanz XrTofacitinib Citrate63$477,170
Humira(Cf) PenAdalimumab36$333,964
Humira(Cf)Adalimumab17$180,078
Orencia ClickjectAbatacept17$103,896
Enbrel MiniEtanercept13$90,248
EnbrelEtanercept11$84,562
OrenciaAbatacept12$69,734
Bosentan11$39,335
Hydroxychloroquine Sulfate916$29,739
TymlosAbaloparatide11$26,931
OtrexupMethotrexate/Pf20$16,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Mallinckrodt Hospital Products Inc.Acthar$27,843$1,031,86111 claims
AbbVieRinvoq, Humira(Cf), Linzess$93,612$972,756148 claims
AmgenKrystexxa, Enbrel$80,257$597,63329 claims
E.r. Squibb & Sons, L.L.C.Orencia$1,127$69,73412 claims
Actelion Pharmaceuticals US, Inc.Bosentan$60$39,33511 claims
Radius Health, Inc.Tymlos$427$26,93111 claims
Antares Pharma, Inc.Otrexup$56$16,51320 claims
Hikma Pharmaceuticals USABuprenorphine$86$13,00531 claims
Scilex Pharmaceuticals Inc.Colchicine$38$5,04157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 rheumatology providers in Georgia.

Other rheumatology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →